VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

Archives of Virology

Volumn 161, Issue 9, 2016, Pages 2449-2455

  Sun, Ming ^a,b,c   Li, Yue ^a,b,d   Yuan, Zhe ^a,b   Lu, Wuxun ^a,b   Kang, Guobin ^a,b   Fan, Wenjin ^a,b   Li, Qingsheng ^a,b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b UNIVERSITY OF NEBRASKA   (United States)

^c INSTITUTE OF MEDICAL BIOLOGY   (China)

^d NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VRC01 MONOCLONAL ANTIBODY;

ANIMAL; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INBRED MOUSE STRAIN; MOUSE; RECTUM; VAGINA; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED STRAINS; RECTUM; VAGINA;

EID: 84976259402     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-016-2942-4     Document Type: Article

References (42)

1. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J et al (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636–640
2. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL et al (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289
3. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856–861
4. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P et al (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466–470
5. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK et al (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633–1637
6. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS et al (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406–412
7. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H et al (2011) Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289–1293
8. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R et al (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336–343
9. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF et al (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci 109:E3268–E3277
10. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S et al (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:118–122
11. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM et al (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:0008805
12. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q et al (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9:343–346
13. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN et al (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:15
14. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G et al (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302–1313
15. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D et al (1999) Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009–4018
16. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE et al (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–210
17. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E et al (2009) A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 343:65–67
18. Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL et al (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109:18921–18925
19. Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang Z-Y et al (2015) Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J Virol 89:5895–5903
20. Veselinovic M, Preston Neff C, Mulder LR, Akkina R (2012) Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432:505–510
21. Hatziioannou T, Evans DT (2012) Animal models for HIV/AIDS research. Nat Rev Microbiol 10:852–867
22. Evans DT, Silvestri G (2013) Nonhuman primate models in AIDS research. Curr Opin HIV AIDS 8:255–261
23. Deruaz M, Luster AD (2013) BLT humanized mice as model to study HIV vaginal transmission. J Infect Dis 208(Suppl 2):S131–S136
24. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA et al (2006) Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 12:1316–1322
25. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK et al (2007) Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204:705–714
26. Brehm MA, Shultz LD, Luban J, Greiner DL (2013) Overcoming current limitations in humanized mouse research. J Infect Dis 208:S125–S130
27. Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, Finzi A et al (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811–817
28. Wu X, Zhang Z, Schramm Chaim A, Joyce MG, Do Kwon Y, Zhou T et al (2015) Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 161:470–485
29. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C et al (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593–1602
30. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P et al (2013) Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39:245–258
31. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME et al (2015) Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 182:289–301
32. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P et al (2015) Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 7:319ra206–319ra206
33. Wang LX, Kang G, Kumar P, Lu W, Li Y, Zhou Y et al (2014) Humanized-BLT mouse model of Kaposi’s sarcoma-associated herpesvirus infection. Proc Natl Acad Sci USA 111:3146–3151
34. Li Q, Tso FY, Kang G, Lu W, Li Y, Fan W et al (2015) Early initiation of antiretroviral therapy can functionally control productive HIV-1 infection in humanized-BLT mice. J Acquir Immune Defic Syndr 69:519–527
35. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A et al (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439–1452
36. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z et al (2011) Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121:2401–2412
37. Lee FH, Mason R, Welles H, Learn GH, Keele BF, Roederer M et al (2015) Breakthrough virus neutralization resistance as a correlate of protection in a nonhuman primate heterologous simian immunodeficiency virus vaccine challenge study. J Virol 89:12388–12400
38. Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS et al (2014) Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88:12669–12682
39. Mascola JR (2002) Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20:1922–1925
40. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:81–84
41. Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS et al (2014) Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20:296–300
42. Della-Porta AJ, Westaway EG (1978) A multi-hit model for the neutralization of animal viruses. J Gen Virol 38:1–19